{"entity":{"id":"nct07750158","kind":"trial","name":"Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease","aka":["STELLAR-316"],"tldr":"A phase 3 trial of zanzalintinib and pembrolizumab in colorectal cancer, run by Exelixis, now recruiting.","summary":"Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease is a phase 3, randomised interventional study registered as NCT07750158 by Exelixis, with a registry enrolment figure of 600 participants, started 2026-08-25 and due to reach its primary completion in 2030-04-05. Interventions recorded: Zanzalintinib; Pembrolizumab (+) Berahyaluronidase alfa; Placebo. Conditions listed: Colorectal Cancer. Primary outcome: Disease-Free Survival (DFS) in Zanzalintinib + MK-3475A Versus Placebo as Assessed by the Investigator; DFS in Zanzalintinib Monotherapy Versus Placebo as Assessed by the Investigator. Colorectal eligibility wording from the registry: \"* Histologically confirmed diagnosis of Stage II or III adenocarcinoma of colon or rectum\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07750158","url":"https://clinicaltrials.gov/study/NCT07750158"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","mrd-testing"],"targets":[],"drugs":["zanzalintinib","pembrolizumab"],"companies":["exelixis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07750158","phase":"3","setting":"Randomized Phase 3 Study of Zanzalintinib ± Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) Versus Placebo in Participants With Colorectal Cancer With Stage II/III Molecular Residual Disease Following Definitive Therapy","sponsor":"Exelixis","enrolled":600,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07750158/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"zanzalintinib","kind":"drug","name":"Zanzalintinib","route":"/drugs/zanzalintinib/"}],"company":[{"id":"exelixis","kind":"company","name":"Exelixis","route":"/companies/exelixis/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}